Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 11 - 20 of about 169   

Articles published

GSK 1,372.75 -5.75 (-0.42%)
price chart
Forget About 2015: Why GlaxoSmithKline plc Should Enjoy Stunning Long-Term ...
Still, firm earnings growth at the company is anticipated to remain elusive for some time to come given the impact of patent stripping.
GlaxoSmithKline plc Earns Buy Rating from Beaufort Securities (GSK)  Ticker Report
Morningstar Issues "A+" Credit Rating to GlaxoSmithKline plc (GSK)  sleekmoney
Related articles »  
Could You Double Your Money With GlaxoSmithKline plc?
GSK's share price rise represents a compound annual growth rate (CAGR) of 3.3%. Earnings per share (EPS) have increased at a CAGR of just 1.4%, with the remainder of the share price rise coming from an increase in the price-to-earnings (P/E) ratio.
Related articles »  
GlaxoSmithKline plc Rating Reiterated by BNP Paribas (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its �underperform� rating reaffirmed by stock analysts at BNP Paribas in a report issued on Wednesday.
GlaxoSmithKline plc Stock Rating Reaffirmed by BNP Paribas (GSK)  WKRB News
Related articles »  
Will GlaxoSmithKline plc Be Back To Growth By 2016?
A few years ago GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) was looking stronger than rival AstraZeneca, with its more promising pipeline and better acquisition strategy offering better protection from the loss of patent protection on key drugs.
Credit Suisse Reiterates Underperform Rating for GlaxoSmithKline plc (GSK)  sleekmoney
GlaxoSmithKline plc Stock Rating Reaffirmed by JPMorgan Chase & Co. (GSK)  Ticker Report
Related articles »  
3 Black Friday Bargains: Barclays PLC, GlaxoSmithKline plc And Tesco PLC
It's one of the biggest shopping weeks of the year, with Black Friday whipping consumers into a pre-Christmas frenzy by offering huge discounts in the shops.
Related articles »  
Are GlaxoSmithKline's (GSK) Restructuring Efforts Enough For Investors?
This year GlaxoSmithKline plc (ADR) (NYSE:GSK) has been focused on one word: �restructuring,� as CEO Sir Andrew Witty remains in search for strong growth drivers in the face of a threatened top-line.
GlaxoSmithKline plc Reaches New 1-Year Low at $41.32 (GSK)  WKRB News
Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (ADR) (NYSE:GSK), Sanofi SA ...
Related articles »  
Bank Of America Downgrades GSK On Low Profit Expectations
Bank of America Corp (NYSE:BAC) Merrill Lynch downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) stock yesterday from Neutral to Underperform, and reduced the target price from $54 to $45.
Thursday Closing Bell Highlights: GlaxoSmithKline plc (GSK), Emerson Electric ...
Closing out the day today, GlaxoSmithKline plc (GSK) of the Healthcare ended with a price at $43.29 and a relative volume of 1.06.
GlaxoSmithKline plc Receives Neutral Rating from JPMorgan Chase & Co. (GSK)
GlaxoSmithKline plc logo JPMorgan Chase & Co. reiterated their neutral rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report sent to investors on Tuesday morning.
GlaxoSmithKline plc Downgraded by Bank of America (GSK)  Ticker Report
GlaxoSmithKline plc's "Neutral" Rating Reiterated at JPMorgan ...  Mideast Time
Related articles »  
Healthcare Sector Movers: Merck & Co. Inc. (MRK), GlaxoSmithKline plc (GSK ...
GlaxoSmithKline plc (GSK) of the Healthcare sector (Drug Manufacturers - Major) moved by 0.83% since open at mid-day today.
Related articles »